Arginine substitutions in the hinge region of antichymotrypsin affect serpin β-sheet rearrangement

Nature Structural Biology

Volumn 3, Issue 10, 1996, Pages 888-893

  Lukacs, Christine M ^a   Zhong, Joan Q ^a   Plotnick, Michael I ^a   Rubin, Harvey ^a   Cooperman, Barry S ^a   Christianson, David W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN INHIBITOR; SERINE PROTEINASE INHIBITOR;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ENZYME ACTIVE SITE; ENZYME CONFORMATION; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARGININE; CHYMOTRYPSIN; CRYSTALLOGRAPHY, X-RAY; PROTEIN FOLDING; SERPINS;

EID: 0029740170     PISSN: 10728368     EISSN: None     Source Type: Journal    
DOI: 10.1038/nsb1096-888     Document Type: Review

References (65)

1. Gettins, P., Patston, P.A. & Schapira, M. Structure and mechanism of action of serpins. Hemat./Oncol. Clin of North America 6, 1393-1408 (1992).
2. Potempa, J., Korzuss, E. & Travis, J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. Biol. Chem. 269, 15957-15960 (1994).
3. Schulze, A.J., Huber, R., Bode, W. & Engh, R.A. Structural aspects of serpin inhibition. FEBS Lett. 344, 117-124 (1994).
4. Travis, J. & Salvesen, G.S. Human plasma proteinase inhibitors. Ann. Rev. Biochem. 52, 655-709 (1983).
5. Remold-O'Donnell, E. The ovalbumin family of serpin proteins. FEBS Lett. 315, 105-108 (1993).
6. Doolittle, R.F. Angiotensinogen is related to the antitrypsin-antithrombin-ovalbumin family. Science 222, 417-419 (1983).
7. Pemberton, P.A., Stein, P.E., Pepys, M.B., Potter, J.M. & Carrell, R.W. Hormone binding globulins undergo serpin conformational change in inflammation. Nature 336, 257-258 (1988).
8. Hirayoshi, K. et al. HSP47: a tissue-specific, transformation-sensitive, collagen-binding heat shock protein of chicken embryo fibroblasts. Mol. Cell. Biol. 11, 4036-4044 (1991).
9. 1-Proteinase inhibitor: crystal structure analysis of two crystal modifications, molecular model, and preliminary analysis of the implications for function. J. Mol. Biol. 177, 531-556 (1984).
10. Schecter, I. & Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Comm. 27, 157-162 (1967).
11. 1-antichymotrypsin at 2.7 Å resolution and its comparison with other serpins. J. Mol. Biol. 218, 595-606 (1991).
12. Baumann, U., Bode, W., Huber, R., Travis, J. & Potempa, J. Crystal structure of cleaved equine leucocyte elastase inhibitor determined at 1.95 Å resolution. J. Mol. Biol. 226, 1207-1218 (1992).
13. Mourey, L., Samama, J.-P., Delarue, M., Petitou, M., Choay, J. & Moras, D. Crystal structure of cleaved bovine antithrombin III at 3.2 Å resolution. J. Mol. Biol. 232, 223-241. (1993).
14. Bruch, M., Weiss, V. & Engel, J. Plasma serine proteinase inhibitors (serpins) exhibit major conformational changes and a large increase in conformational stability upon cleavage at their reactive sites. J. Biol. Chem. 263, 16626-16630 (1988).
15. Gettins, P., & Harten, B. Properties of throbin- and elastase-modified human antithrombin III. Biochemistry 27, 3634-3639 (1988).
16. 1-antitrypsin, antithrombin, and the mechanism of inflammatory thrombosis. Nature 317, 730-732 (1985).
17. 1H nuclear magnetic resonance and Fourier transform infrared spectroscopy. J. Mol. Biol. 228, 1235-1254 (1992).
18. Wei, A., Rubin, H., Cooperman, B.S. & Christianson, D.W. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nature Struct. Biol. 1, 251-258 (1994).
19. Carrell, R.W., Evans, D.L. & Stein, P.E. Mobile reactive centre of serpins and the control of thrombosis. Nature 353, 576-578 (1991).
20. 1-antitrypsin by a peptide sequentially similar to β-Strand s4A. Eur. J. Biochem. 194, 51-56 (1990).
21. 1-Proteinase inhibitor variant T345R. Influence of P14 residue on substrate and inhibitory pathways. Biochemistry 33, 8538-8547 (1994).
22. 1-antitrypsin to its reaction with elastase. Biochemistry 34, 15872-15879 (1995).
23. Lawrence, D.A., Olson, S.T., Palaniappan, S. & Ginsburg, D. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J. Biol. Chem. 269, 27657-27662 (1994).
24. Tucker, H.M., Mottonen, J., Goldsmith, E.J. & Gerard, R.D. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nature Struct. Biol. 2, 442-445 (1995).
25. Katz, D.S., Wei, A., Zhong, Q., Rubin, H., Cooperman, B.S. & Christianson, D.W. Crystallization and atomic resolution X-ray diffraction analysis of antichymotrypsin variants. Biochem. Biophys. Res. Comm. 196, 752-757 (1993).
26. Gils, A., Knockaert, I. & Declerck, P.J. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 35, 7474-7481 (1996).
27. Aertgeerts, K., De Bondt, H.L., De Ranter, C.J. & Declerck, P.J. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nature Struct. Biol. 2, 891-897 (1995).
28. Audenaert, A.-M., Knockaert, I., Collen, D. & Declerck, P.J. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive site loop. J. Biol. Chem. 269, 19559-19554 (1994).
29. Carrell, R.W. & Stein, P.E. The biostructural pathology of the serpins: critical function of sheet opening mechanism. Biol. Chem. Hoppe-Seyler 377, 1-17 (1996).
30. Sancho, E., Declerck, P.J., Price, N.C., Kelly, S.M. & Booth, N.A. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms. Biochemistry 34, 1064-1069 (1995).
31. Wright H.T., & Blajchman, M.A. Proteolytically cleaved mutant antithrombin-Hamilton has high stability to denaturation characteristic of wild type inhibitor serpin. FEBS Lett. 348, 14-16 (1994).
32. Gettins, P., Patston, P., & Schapira, M. The role of conformational change in serpin structure and function. BioEssays 15, 461-467 (1993).
33. Wright, H.T., & Scarsdale, J.N. Structural basis for serpin inhibitor activity. Proteins: Struct., Funct., Gen. 22, 210-225 (1995).
34. Stites, W.E., Gittis, A.G., Lattman, E.E., & Shortle, D. In a staphylococcal nuclease mutant the side-chain of a lysine replacing valine 66 is fully buried in the hydrophobic core. J. Mol. Biol. 221, 7-14 (1991).
35. Dao-pin, S., Anderson, D.E., Baase, W.A., Dahlquist F.W., & Matthews, B.W. Structural and thermodynamic consequences of burying a charged residue within the hydrophobic core of T4 lysozyme. Biochemistry 30, 115221-111529 (1991).
36. 1-proteinase inhibitor. J. Mol. Biol. 213, 513-528 (1990).
37. Stein, P.E., Tewkesbury, D.A. & Carrell, R.W. Ovalbumin and angiotensinogen lack serpin S→R conformational change. Biochem. J. 262, 103-107 (1989).
38. 1-proteinase inhibitor variants. Eur. J. Biochem. 202, 1147-1155 (1991).
39. Skriver, K. et al. Substrate properties of C1 inhibitor Ma (Alanine 434→Glutamic Acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor inhibitor/substrate status. J. Biol. Chem. 266, 9216-9221 (1991).
40. Davis, A.E. et al. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nature Genetics 1, 354-358 (1992).
41. Lawrence, D.A. et al. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J. Biol. Chem. 270, 25309-25312 (1995).
42. 1-antitrypsin. Nature Struct. Biol. 3, 497-500 (1996).
43. Ireland, H. et al. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin. Brit. J. Haem. 79, 70-74 (1991).
44. Hopkins, P.C.R., Carrell, R.W., & Stone, S.R. Effects of mutations in the hinge region of serpins. Biochemistry 32, 7650-7657 (1993).
45. 1-antitrypsin reveals the conformation of its inhibitory reactive loop. FEBS Letters 377, 150-154 (1995).
46. Wilczynska, M., Fa, M., Ohlsson, P.-I. & Ny, T. The inhibition mechanism of serpins. J. Biol. Chem. 270, 29652-29655 (1995).
47. Carrell, R.W., Stein, P.E., Fermi, G. & Wardell, M.R. Biological implications of a 3 Å structure of dimeric antithrombin. Structure 2, 257-270 (1994).
48. Schreuder, H.A. et al. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nature Struct. Biol. 1, 48-54 (1994).
49. Stein, P.E. & Carrell, R.W. What do dysfunctional serpins tell us about molecular mobility and disease? Nature Struct. Biol. 2, 96-113 (1995).
50. Plotnick, M.I., Mayne, L., Schechter, N.M. & Rubin, H. Distortion of the active site of chymotrypsin complexed with a serpin. Biochemistry 35, 7586-7590 (1996).
51. Stavridi, E.S. et al. Structural change in α-chymotrypsin induced by complexation with α1-antichymotrypsin as seen by enhanced sensitivity to proteolysis. Biochemistry 35, 10608-10615 (1996).
52. Dixon, M.M. & Matthews, B.W. Is γ-chymotrypsin a tetrapeptide acylenzyme adduct of α-chymotrypsin? Biochemistry 28, 7033-7038 (1989).
53. 1-antichymotrypsin. J. Biol. Chem. 265, 1199-1207 (1990).
54. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Cryst. 24, 795-800 (1993).
55. Leslie, A.G.W. Joint CCP4 and ESF-EACMB Newsletter on Protein Crystallography, 26, Warrington, Daresbury Laboratory (1992).
56. Collaborative Computing Project, No. 4. The CCP4 Suite: Programs for protein crystallography. Acta Cryst. D50, 760-763 (1994).
57. Navaza, J. AMoRe: An automated package for molecular replacement. Acta Cryst. A50, 157-163 (1994).
58. Brünger, A.T. Free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 355, 472-475 (1992).
59. Sack, J.S. CHAIN: A crystallographic modeling program. J. Mol. Graphics 6, 224-225 (1988).
60. Brünger, A.T. X-PLOR (v. 3.1)- A system for X-ray crystallography and NMR, New Haven, CT., Yale University Press (1992).
61. Brünger, A.T., Krukowski, A., & Erickson, J.W. Slow-cooling protocols for crystallographic refinement by simulated annealing. Acta. Cryst. A46, 585-593 (1990).
62. 1-Antichymotrypsin into a human neutrophil elastase inhibitor: demonstration of variants with different association rate constants, stoichiometries of inhibition, and complex stabilities. Biochemistry 33, 7627-7633 (1994).
63. Jones, T.A., Cowan, S.W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Cryst. A47, 110-119 (1991).
64. Jones, T.A. & Kjeldgaard, M. O - the Manual (version 5.10), Uppsala (1995).
65. Kraulis, P.J. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Cryst. 24, 946-950 (1991).